BofA raised the firm’s price target on Neurocrine (NBIX) to $199 from $190 and keeps a Buy rating on the shares after the company announced the acquisition of Soleno Therapeutics (SLNO) for $2.9B in equity value. While “encouraged” by the bolt-on acquisition given its immediate accretive revenue allowing Neurocrine to further diversify revenue streams from Ingrezza, the firm also highlights 2026 as “a light pipeline catalyst year” with the primary focus on commercial execution of Ingrezza, Crenessity and now Vykat XR.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Balanced Risk-Reward After Soleno Acquisition Supports Neutral Stance on Neurocrine
- Neurocrine price target raised to $215 from $192 at H.C. Wainwright
- Neurocrine price target raised to $166 from $151 at Baird
- Neurocrine price target raised to $242 from $204 at Citi
- Neurocrine price target raised to $200 from $164 at Canaccord